Gapping up
In reaction to earnings/guidance:
- BOWL +3.4%
Other news:
- NTLA +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
- GOGO +5% (Repurchases 1.5 million shares of common stock from BlackRock)
- ADCT +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHMP opinion for ZYNLONTA for the treatment of relapsed or refractory diffuse large B-cell lymphoma)
- RVNC +2.3% (to present Phase 2 data)
- CELU +1.9% (stock offering)
- AZN +1.6% (reports Danicopan (ALXN2040) add-on to Ultomiris or Soliris met primary endpoint in ALPHA Phase III trial, Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19, Beyfortus (nirsevimab) recommended for approval in the EU by CHMP)
- GENI +1% (secured an agreement with Amazon (AMZN) to provide augmented video technology and data-related services in connection with an alternate feed of Prime Video's Thursday Night Football NFL broadcast in the U.S.)
Analyst comments:
- AA +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
